Get started
Author

Kalpana Antony

Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial
2014 · Nita Bhandari, Temsunaro Rongsen-Chandola, et al. · The Lancet · 326
Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life
2014 · Nita Bhandari, Temsunaro Rongsen-Chandola, et al. · Vaccine · 102
PDF
Diarrheal Etiology and Impact of Coinfections on Rotavirus Vaccine Efficacy Estimates in a Clinical Trial of a Monovalent Human–Bovine (116E) Oral Rotavirus Vaccine, Rotavac, India
2018 · Ira Praharaj, James A Platts-Mills, et al. · Clinical Infectious Diseases · 49
PDF
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial
2021 · Ed Clarke, Adedapo Bashorun, et al. · The Lancet Infectious Diseases · 38
PDF
ROTAVAC ® does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial
2017 · Temsunaro Rongsen Chandola, Sunita Taneja, et al. · Heliyon · 32
PDF
Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India
2014 · Jacob John, Anand Kawade, et al. · Vaccine · 29
PDF
Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9–14 years of age: Interim analysis from a phase 3 clinical trial
2024 · Khalequ Zaman, Anne E Schuind, et al. · Vaccine · 23
Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine
2018 · Sajjad Desai, Niraj Rathi, et al. · Vaccine · 20
A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants
2018 · Niraj Rathi, Sajjad Desai, et al. · Vaccine · 19
Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9–14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial
2025 · Tsiri Agbenyega, Anne E Schuind, et al. · The Lancet Infectious Diseases · 14
Assessment of risk of intussusception after pilot rollout of rotavirus vaccine in the Indian public health system
2020 · Nita Bhandari, Kalpana Antony, et al. · Vaccine · 14
PDF
Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial
2023 · Ikechukwu Adigweme, Ahmed Futa, et al. · The Lancet Infectious Diseases · 13
PDF
Immunogenicity and Safety of Escherichia Coli-Produced Bivalent Human Papillomavirus Vaccine in Girls 9–14 Years of Age in Low- and Middle-Income Countries: Final Data of Randomized Controlled Trial
2024 · Tsiri Agbenyega, Anne E. Schuind, et al. · SSRN Electronic Journal
Response to: Letter from P. Gillard and B. Benninghoff
2019 · Niraj Rathi, Sajjad Desai, et al. · Vaccine
Works count: 14
Citation count: 679
H-index: 12
I10-index: 12
Year
Topic
Type